involved in I and time healthy the to to our eye the acknowledge were during you providers this in thank for ONSET-X and opportunity joining safe lives. Dan, would hoping I’m morning. us you, the their to trial. families are care everyone this that take and patients, unique like Thank everyone the staff that and
The in of ONSET-X completed March XXXX. and XXXX of study began enrollment July in
coronavirus began the the March, of we system general impact care to investigational continued health treatment safely were patients in the fortunate of data amazing such in who to centers complete pandemic U.S. the work Phase and clinical needed and III collect study. the this group with to to an phase As and honored the
refer For number those website, available of our the four. that with on you slide deck corporate following along we made please slide to
to Phase the doses, as excited to as doses per mean the change treatment ONSET-X nasal spray in from the data milligram endpoint of ONSET-X the primary consistent baseline ONSET-X XX our study signs Score has compared announcing ml day endpoint met been disease. are dry trial. We trial, also symptoms and to III four. outcome the translated This per a a and a milligram improvement secondary Schirmer’s statistically X.X or both with in from significant control in X.X our today The for in Schirmer’s its significant designed of four both positive at which statistically week investigate clinical at of into eye be with improvement OC-XX the week OC-XX Score result achieving in ml
Benefits endpoints the filing at the Pharma milestone news eye NDA were including score as clinic of the baseline ml the also look group, four toward major from and in team half first XXXX. as the in Today’s for early mean seen the milligram as is on Point week Oyster in dryness per dose second our of week a environment two. on we a number X.X change of secondary
the to here of turn ONSET-X X. summarized design Slide Please study is on X. The Slide
Phase we per daily eye of randomized of who were or subjects III to you see, or either XXX July least in an milligrams is care eye placebo diagnosis ONSET a XXXX. X.X of ml at disease XX receive milligrams As will ml provider’s for with years which were double-masked, per weeks. study X.X dry age the four twice initiated randomized, multicenter, trial, placebo-controlled
primary with XX Score course time baseline. of five-minute from study anesthetized The The lower criteria baseline percentage week subjects at Score anesthetized test period Schirmer’s is objective produced a was margin. enrollment of measure this by Schirmer’s or in placing of The four. primary endpoint the a for amount millimeters is increase XX a an the of was less an having lid that the Schirmer’s strip over into tear film at the of
score the Key eye include as as environment clinic environment four. endpoints the assessing within dryness week well secondary controlled adverse at
included week endpoints staining secondary as at two assessment inferior assessments as week score corneal dryness Additional of in clinic and eye at the one. well
number run-in turn ONSET-X development trial is not the this clinical understand clinical a six. important been design consistently aspects are element designed a any of the part when placebo of our trial of general phases. This and in and interpreting clinical Oyster has results. Pivotal There to the to program that Please important of dry eye trials Point not have Slide been in are trials. trial with required
symptom and the dryness a of ONSET-X there no requirements in subjects population. wide are In study, the are spectrum score, therefore, – study dry with included eligibility eye severity for
So feel settings population of the ONSET-X study broad clinical the population. translate the study are relevant design the We of eye generally into wide spectrum of included symptom to trial will that severity real-world reflect patients. a dry that in outcomes
strategize not also will will the factors study as how clinical armamentarium. scale. study, the the care fluorescein grading staining a proparacaine ONSET-X we a The multiple at in due investigate show well benefit and results use staining, to allow environment, the translate practice In in therefore, treatment into of controlled trial as designed Eye outcomes confounding And their of product although staining is practitioners Institute used trial use and, this adverse this to in National to to see ONSET-X use in this corneal did corneal trial. a the visits eye this we benefit
turn Please to X. Slide
an typically to of eye Subjects' well Score more and a characteristics, eye the Schirmer’s Score see demographics, with study population Baseline epidemiology predominantly as you millimeters. trials characteristics dryness dryness clinical XX age treatment the with regards with of eye ONSET-X eye is eye baseline disease compared to seen groups clinical and consistent baseline dry also previously contains from much score as healthier see average Schirmer’s our enrolled population females baseline that As score. dry with than were The population trial. in dryness consistent from baseline and is represent score completed males. the we balanced
to turn Slide X. Please
see indicating you of X.X per and percentage compared a or millimeters significant treatment milligram more XX placebo. primary of subjects statistically per in as gain ml groups achieving Here, the X.X milligram endpoint ml the both to
of subjects in Schirmer’s ml subjects XX% For on four, gaining treatment the X.X subjects four baseline those XX greater X.X in responder group. change from of and of Schirmer’s per to groups of control the to XX% analysis Score in as achieved subjects at week XX% or a in Score the at millimeters milligram the compared equal week than
for consistent the illustrates and slide This from X. the studies reproducible Slide to endpoint. ONSET-X ONSET-X both turn Please and data this
the Schirmer’s comparison, with control the resemble fact compared is regards in to to the that healthier study, supporting Score from ONSET-X in the ONSET-X. population a see that ONSET-X group included the characteristics the higher baseline the of in study you as mean As change
in mean Score change in to the of turn Schirmer’s Illustrated from Slide XX. endpoint Please is slide this baseline at secondary four. week
X.X categorical X.X treatment significance placebo. milligram the achieved compared primary in ml both per with groups was and endpoint, as As statistical to
as treatment in ml Score while milligram of in the Schirmer’s mean group to a control of a X.X mean millimeters X.X group subjects of had millimeters, of per increase in X.X compared increase treatment change in Score ml XX per group. Subjects Schirmer’s the XX.X the a milligram mean had
reproducible Slide Please Schirmer’s study the for to again the change This the and XX. data demonstrates mean slide consistent in ONSET-X compared Score endpoint. turn to as
is study, the see change categorical comparison, the the you with Score the with what we control in Schirmer’s higher can group ONSET-X to the in from As with see endpoint. regards consistent mean
Slide to XX. turn Please
treatment to – change a mean per significant. statistically compared X.X ml group. milligram treatment dryness significant The control an group. XX.X from group there And placebo, endpoint the millimeters XX.X in in directionally [indiscernible] in per as millimeters reduction ml milligram treatment X.X the per minus dry although average compared had score group was eye secondary baseline ml in minus it’s dryness eye as of in to Subjects of score a not the
dose dose per XX. response not see balanced per In Slide clear X.X there to dose this in the milligram X.X the the we and performing with milligram X.X characteristics, turn ONSET-X per group milligram we low trial, the significant where in slide, ml dose. group. In dose ml see comparison we better group ONSET-X, statistically ml in than improvement have the Please was a where baseline
Slide to Please turn XX.
ml milligram The milligram X.X from per two statistically secondary mean in eye at ml and the the in was X.X had the the XX.X environment baseline in dryness as an average eye X.X a millimeters in endpoint XX.X in score reduction compared minus milligram to per dryness of significant mean millimeters score assessed change average had while in score treatment ml X.X eye placebo in of week treatment of group. change treatments to minus per group clinic reduction the minus both compared Subjects in of subjects control. dryness group XX.X millimeters as an
spray this nasal dry important seeking with will eye the patients We disease. OC-XX early the discomfort from and on of highlights symptoms relief believe associated and are that benefit that be irritation for
Please turn to Slide XX.
of secondary change Here, one. in eye dryness clinic week endpoint baseline mean we the in assessed score environment see at from the
there dose week significant. at both Although a benefit statistically doses, one was directional was in neither
milligram effect turn to symptom we of with slide time increase consistent ONSET-X in see therapy. ml improvement a the in This over summarizes over the the where clinical in in trial, continued X.X the dose magnitude group time Please XX. per Slide scores
to XX. Slide Please turn
or change endpoint adverse was assessed week not score per statistically of secondary environment to at milligram either from ml significant control. The X.X treatment baseline X.X dryness four the on groups eye compared as controlled in mean the in
As by you significantly. the size will size was factors see, endpoint of that analysis the and the two main reduced sample sample affected impacted
of sites their pandemic feel The environment subjects who chamber was putting comfortable adverse unfolding. and/or controlled as number not coronavirus into pandemic did impacted staff the a the
were FDA did our and In in the for agency prior in that for due Since and time. plan submission. meet unmasking change the context to addition, We contact this the the lock with a to will database pandemic not while the number statistical to treatment instructed address two therefore the criteria were so were endpoint, in hours asymptomatic full the with analysis of database, the group in not each and of coronavirus subjects to we NDA how at discussed do we have chamber.
that slide adverse however, the benefits is feel, do We subjects controlled XX. of the Slide to turn nasal entered dataset Please useful highlighting environment. score rich illustrates for symptom assessment OC-XX spray patients. this the the before in The
ml as per change group dryness in the to As score a X.X the millimeters millimeters of minus reduction placebo in had treatment see, compared subjects a in milligram you XX.X mean minus significant eye of statistically XX.X group.
last time impressive symptom a OC-XX nasal about the as evening of durability most XX the Please prior the morning as for administered effect is this is significant protocol with frame treatment, OC-XX of that to before Slide could reduction the in reduction represented the What score XX was to turn long believe seen dose that symptom nasal subject chamber have assessment. withholding to as the illustrates that statistically symptom to spray. spray this We specifies the the XX. hours
the high-airflow represents This controlled the dryness environment. hours eye graph mean in the two are adverse this in line full for low-humidity, that score environment subjects placed
and environmental as or nasal that chamber persistent and that resist in disease. over placebo air the As environment. significant such this in many This experience data with dose milligram graph, the one that environment believe ability We conditions ml from of adverse flatten to OC-XX illustrates separation heating change spray a forced shows this illustrated time. dry an would the eye in X.X separate exacerbates patients simulates in to continues airplane per group symptoms
Institute fluorescein turn in the using XX. study Eye this assessed was staining Inferior to staining Please corneal scale. National Slide fluorescein
and of this group Although and proparacaine administration for regular controlled although directional not per by staining, milligram results inferior corneal benefit to fluorescein no benefit on environment, indicate the X.X staining designed testing adverse dose ml a there any the statistical due nasal was Schirmer’s of the anesthetized the caused in assess was confounding favoring potential the corneal regions. to study
to turn Slide XX. Please
was number staining group. the X.X primary a milligram groups, this to endpoints favoring ml statistically categorical in Schirmer’s endpoint both XX. statistically by illustrated As significant, benefit the dose regions per a of of in slide, there Score although secondary group. corneal X.X all summary, directional Please milligram as not per in dose was In significant the fluorescein Slide dose in change were ml turn
mean stated submission will of discussing be NDA. dryness environment As earlier change slides, at in controlled of time in endpoint the a the in eye of we secondary the adverse the score
useful eye care data, and data the increase turn group, the trial the ONSET-X natural natural tear with a the with patient believe Slide completed as nasal that We will four. an film we film, to improvement significant mechanism of for that treatment eye help important a the at from signs support as of milligram clinically in XX. week previously ONSET-X action as Please dose study, as per indication statistically OC-XX of for and compared care support this results will product to X.X two believe professional. early meaningful the with symptoms In control. be magnitude the establish In effect stimulating to we unique an ml the see symptoms the practitioner. significant week in of will We production tear of statistically spray see increasing
in a illustrates slide This XX. summary Slide the to study. of turn ONSET-X Please adverse events
of drug. X% a treatment group. experience There events we adverse the the higher related There The treatment across leading serious primarily sneezing. number than similar adverse subjects events group study a in number were event was most events event, adverse emergent of groups all adverse treatment treatment treatment an adverse to less no driven by common to see all of are ocular across any these subjects discontinuation Although events in groups. of with number were
in related turn by leading event both treatment sneezing X% study drug that in common XX% from to with irritation groups. subjects XX% of reported study This events cough. consistent most or group. data dose ONSET-X of of The newly the than each the mild. are Slide followed considered discontinuation is adverse Nasal Greater than equal less less in with was than Treatment-related no the trial signal. Please were clinical adverse to were were XX. identified to throat and safety to events
no nasal stinging no events ocular or the to adverse surface. there were nasal on surface, spray serious burning There administration. events reports the of because spares spray OC-XX were ocular Importantly, of related
of from from more Slide most turn the of severity in mild A adverse administration data, nasal Approximately treatment in sneezing. summarizes administration slide diary. experienced to than with with was administrations following event XX. spray nasal number first the administration. associated XX% were common the the where collected the the Please majority administrations XX% subjects agreement minute was of sneezes In data within group sneezing, all in was adverse subjects. sneezing experienced each This to noted. which with patient zero sneezes was at spray majority of transient Sneezing occurring two events
XX. Slide to turn Please
we see have MYSTIC well dry the encompass will study bioavailability Point’s days four August clinical U.S. disease In and or program. from the XX studies As ZEN of clinical here, twice-daily released eye as OC-XX XXXX, the clinical OC-XX January, that enrolled ONSET-X dosing development ONSET-X the you development nasal results Oyster since program consists spray. started of as studies. investigating of study the we
these results the on to product We With will half OC-XX spray an help track ONSET-X study, treatment XXXX. an the nasal in are of for the believe establish mechanism the as submit second eye unique to NDA from we application positive care the professional. action of this that important FDA for
XX. a and tear ultimately over is volume decreased ocular to inflammation in ocular the damage chronic, homeostasis characterized increased film the of to time loss eye Please of disease of Dry progressive – team disorder and/or by leads surface to homeostasis. turn a the evaporation Slide resulting This irritation, over loss surface.
produce to natural using that multifactorial to OC-XX effectively. difficult varenicline. parasympathetic receptor a the spray Dry action cholinergic of complex treat The agonist, tear disease of mechanism nasal novel pathway the is is eye disease trigeminal and stimulates film
components Natural body’s consists there of for of growth no of inherently surface believe we and symptomatic mixture substitute of is relief to in provide the hydrating thousands ocular film homeostasis. is antimicrobial will compounds an tear therapy with film. a natural that including anti-inflammatory lubricating tear Please film to while and complex OC-XX components disruption the the beneficial underlying and tear sustained XX. own turn factors, treating provides compounds, Currently, nature. Slide early
to I’d Snisarenko. Commercial Chief to the ahead. turn John John, Point’s go call Now over please Officer, Oyster like
